Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINUTE
2024-518878-14-01Phase 4Authorised
- Sponsor
- Isala
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab, pembrolizumab, ipilimumab, bevacizumab, trastuzumab and 8 more in inflammatory bowel disease (IBD), rheumatism and cancer, sponsored by Isala. Primary endpoints: Number of infusion-related reactions and Grade of infusion-related reactions. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)rheumatismcancer
Beyond the preview
Go deeper on 2024-518878-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518878-14-01.